Results 1 to 10 of about 5,497 (140)

Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway [PDF]

Frontiers in Pharmacology
ObjectivesThis investigation sought to explore the inhibitory impact of wogonin on prolactinoma and elucidate its underlying mechanisms through network pharmacology, molecular docking (MD), and molecular biology experiments.MethodsTarget identification ...
Zhiyong Du, Zhiyong Du, Zhiyong Du, Zhiyong Du, Cuiping Sun, Cuiping Sun, Cuiping Sun, Cuiping Sun, Jiawei Wu, Jiawei Wu, Hongwei Gao, Hongwei Gao, Hongwei Gao, Hongwei Gao, Jialong Wu, Jialong Wu, Jialong Wu, Jialong Wu, You Zhou, You Zhou, You Zhou, You Zhou, Xuechao Wu, Xuechao Wu, Liping Shen, Liping Shen, Qing Wang, Qing Wang, Qing Wang, Qing Wang   +29 more
doaj   +2 more sources

Prolactinomas [PDF]

JAMA, 2021
Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including ...
Pauline P, Huynh, Lisa E, Ishii, Masaru, Ishii   +2 more
openaire   +4 more sources

Descriptive Epidemiology and Survival Analysis of Prolactinomas and Cushing’s Disease in Korea [PDF]

Endocrinology and Metabolism, 2021
Background Only a few studies have established the epidemiology of prolactinoma and Cushing’s disease in Korea. Furthermore, the incidence of these disease are increasing than before associated with the development of technologies.
Jin Sun Park, Soo Jin Yun, Jung Kuk Lee, So Young Park, Sang Ouk Chin   +4 more
doaj   +1 more source

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance [PDF]

Acta Neuropathologica Communications
Prolactinoma is the most prevalent pituitary neuroendocrine tumor and dopamine agonists (DAs) targeting dopamine D2 receptor (DRD2) are recommended as the first-line treatment. However, varying degrees of DA resistance limit patient benefit.
Yuyang Peng, Huachun Yin, Xiangdong Pei, Yuan Zhang, Chengcheng Wang, Xin Zheng, Hong Liang, Hui Yang, Song Li   +8 more
doaj   +2 more sources

The Effect of Prolactinoma on Tear Film Function

Türk Oftalmoloji Dergisi, 2022
Objectives:To compare dry eye parameters in prolactinoma patients and healthy controls and evaluate their correlation with prolactin (PRL) levels and the duration of hyperprolactinemia.Materials and Methods:Consecutive patients with prolactinoma and ...
Cezmi Doğan, Ümit Yaşar Güleser, Oğuzhan Kılıçarslan, Burak Mergen, Özer Açbay, Güzin İskeleli   +5 more
doaj   +1 more source

Prolactinoma [PDF]

Arquivos Brasileiros de Endocrinologia & Metabologia, 2014
Os prolactinomas são os adenomas de hipófise mais comuns e frequentemente afetam mulheres jovens, em faixa etária de fertilidade. A hiperprolactinemia causa hipogonadismo, irregularidade menstrual ou amenorreia em mulheres, níveis baixos de testosterona sérica em homens e infertilidade e disfunção sexual em ambos os gêneros.
Glezer, Andrea, Bronstein, Marcello D.
openaire   +4 more sources

Inhibiting MAPK14 showed anti-prolactinoma effect

BMC Endocrine Disorders, 2020
Background The specific underlying pathogenesis of prolactinoma has not been clarified yet, to the best of our knowledge. p38 mitogen-activated protein kinase (MAPK) signaling including p38α MAPK (MAPK14), p38β (MAPK11), p38γ (MAPK12) and p38δ (MAPK13 ...
Qiao-yan Ding, Yu Zhang, Li Ma, Yong-gang Chen, Jin-hu Wu, Hong-feng Zhang, Xiong Wang   +6 more
doaj   +1 more source

Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma [PDF]

Zhongguo quanke yixue
Pituitary prolactinoma is a neuroendocrine disease caused by excessive pituitary prolactin-cell adenoma synthesis and prolactin secretion. The standardized diagnosis and treatment of pituitary prolactinoma in of great significance for recovering and ...
TAN Huiwen, LI Danting, YU Yerong
doaj   +1 more source

Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study

BMC Endocrine Disorders, 2021
Background Hyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after ...
Anna Sophia Posawetz, Christian Trummer, Marlene Pandis, Felix Aberer, Thomas R. Pieber, Barbara Obermayer-Pietsch, Stefan Pilz, Verena Theiler-Schwetz   +7 more
doaj   +1 more source

Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience

The Turkish Journal of Pediatrics, 2022
Background. Hyperprolactinaemia refers to increased circulating prolactin and is divided into functional and pathological hyperprolactinaemia. Prolactinoma is the most common cause of severe hyperprolactinaemia. Prolactinomas are rare in children.
Tuğba Kontbay, Zeynep Şıklar, Elif Özsu, Rukiye Uyanık, Esra Bilici, Ayşegül Ceran, Merih Berberoğlu   +6 more
doaj   +1 more source